GSK (GSK) shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes cancer.

The London-listed firm said it had struck agreements to resolve 93%, or about 80,000, of the pending Zantac ﷺlawsuits in the U.S. and will make a total p🌼ayment of up to $2.2 billion to settle those cases. 

GSK Says Plaintꦯiffs ꧟Unanimously Recommending Clients Accept Deal

"The participating plaintiff firms are unanimously recommending to their clients that they accept the terms of the State Courts Settlement, which is expected to be fully implemented by the end of H1 2025," GSK said. 

GSK also said it had reached a deal to pay $70 million to settle a Zantac complaint filed by laboratory Valisure, with the agreement subject to final approval from the U.S. Department of Justice (DOJ).

GSK reiterated its previous comments that there 澳洲幸运5官方开奖结果体彩网:isn't evidence that Zantac "increases the risk of any cancer," and said 🌜it has not admitted any liability in the settlements. It said the costs of the settlements will be funded "through existing resources" and that there are no changes to its "growth ꦏagenda or investment plans."

GSK's 澳洲幸运5官方开奖结果体💮彩网:American depositary receipts (ADRs) were littlꦏe changed in premarket trading but ar🥃e up around 9% this year.